Anergis files patent on third product

AllerDM is an allergy vaccine for patients with house dust mite allergy and is based on Anergis’ proprietary Contiguous Overlapping Peptide (COP) technology, which allows for ultra-fast desensitization in only two months treatment. COP allergy vaccines are pharmaceutical quality products, which have proven to be safe and well tolerated and to induce a long-term immune effect. AllerDM is currently in pre-clinical development and is expected to enter clinical stage in 2015.

House dust mites are the most frequent cause of allergy and suspected to trigger severe consecutive disorders. Asthma may be caused by house dust mite allergy in 50 to 80% of patients. It is estimated that about 60 million patients in Europe, 30 million in the U.S., 20 million in Japan and 60 million in China suffer from dust mite allergies.

“Defining COPs for this important new indication illustrates once again the ability of our technology platform to generate products against a broad range of allergies,” said Christophe Reymond, CSO of Anergis. “We are planning to continue discovering, developing and patenting further innovative COP allergy vaccines in the future.”

“In parallel to our AllerT Phase IIb efficacy trial in patients allergic to birch pollen, we are very pleased to have been able to discover and initiate the development of two more products addressing high unmet medical needs,” said Vincent Charlon, CEO of Anergis. “This provides us with fascinating development perspectives."

AllerT, the lead product of Anergis, is currently evaluated in a double-blind, randomized, placebo-controlled Phase IIb trial in 240 patients with moderate to severe birch pollen allergy, enrolled at 24 trial centers throughout Europe. Results are expected in Q3, 2013.

Earlier this year, Anergis presented preclinical data of its ragweed allergy vaccine candidate AllerR. A Phase I/IIa trial of AllerR is expected to start in 2015.